Immune-checkpoint inhibitors for the treatment of metastatic melanoma: a model of cancer immunotherapy.

Immune-checkpoint inhibitors for the treatment of metastatic melanoma: a model of cancer immunotherapy.

Publication date: Aug 17, 2019

Melanoma has always been described as an immunogenic tumor. Despite that, until 2011 the standard of care in metastatic melanoma was chemotherapy, with low response rates and no clear impact on overall survival. Melanoma was the first cancer type to drive the use of immune-checkpoint inhibitors into clinical practice, which revolutionized the therapeutic paradigm not only in melanoma, but also in an increasing number of tumors. In this review, the preclinical bases and the main clinical studies that led to the approval of immune-checkpoint inhibitors in advanced melanoma will be described with insights on novel combinations of treatments and on prognostic and predictive biomarkers.

Queirolo, P., Boutros, A., Tanda, E., Spagnolo, F., and Quaglino, P. Immune-checkpoint inhibitors for the treatment of metastatic melanoma: a model of cancer immunotherapy. 23816. 2019 Semin Cancer Biol.

Concepts Keywords
Biomarkers Immunogenic tumor
Chemotherapy Tumors
Immunogenic Melanoma
Immunotherapy Therapeutic paradigm melanoma
Melanoma Clear survival Melanoma
Paradigm Chemotherapy
Tumor Immunotherapy
Medicine
Clinical medicine
Immune system
Organ systems
Cancer treatments
Melanoma
Checkpoint inhibitor
Immunotherapy
Immune checkpoint
Cancer immunotherapy
Ipilimumab
Chemotherapy

Semantics

Type Source Name
gene UNIPROT RPL17
gene UNIPROT CTLA4
gene UNIPROT IMPACT
disease DOID cancer
disease MESH cancer
pathway BSID Melanoma
disease DOID melanoma
disease MESH melanoma

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *